Curenetics Joins Forces with Queen Mary University London and Oracle Cancer Trust

Curenetics Joins Forces with Queen Mary University London & Oracle Cancer Trust in Revolutionary AI-Enabled Oral Cancer Test- qMIDS Supported by NIHR

Curenetics, Queen Mary University London (QMUL),  Oracle Cancer Trust and South East Health Technologies Alliance (SEHTA) are working collaboratively to pioneer a transformative approach to oral cancer detection through the Novel AI-Enabled qMIDS Test. The research is funded by the National Institute for Health and Care Research (NIHR), the research partner of the NHS, public health and social care. This groundbreaking project is poised to elevate precision cancer diagnostics by harnessing the power of artificial intelligence.

The Novel AI-Enhanced qMIDS Test, an innovative fusion of state-of-the-art technologies, presents a revolutionary solution to the challenge of oral cancer diagnosis. By integrating AI with the quantitative Malignancy Index Diagnostic System (qMIDS), rapid and accurate oral cancer detection is now possible even in the presence of seemingly inconspicuous mouth lesions. The test employs reverse transcription quantitative PCR to analyze the expression levels of 16 genes (mRNA) within a minimally invasive 1-mm3 tissue biopsy. These gene expression profiles are then translated into a clinically meaningful quantitative malignancy index through an AI-powered algorithm, enabling precise stratification of cancer risk.

This cutting-edge research initiative represents a collaboration between the fields of oral cancer medicine, cancer biology and artificial intelligence. The research team is led by Dr. Sola Adeleke, Dr. Muy-Teck Teh, Dr. Barbara Carey, Gemma McKnight, and experts from SEHTA. Together they bring a wealth of expertise and a shared dedication to pushing the boundaries of cancer diagnostics.

Future Implications

Dr. Sola Adeleke, Founder of Curenetics, expressed the immense significance of this partnership: “Our collaboration with Queen Mary University London and Oracle Cancer Trust, under the auspices of NIHR, marks a giant stride in validating the Novel AI-Enhanced qMIDS Test. This research holds the potential to revolutionize the way we approach cancer diagnosis, offering an unprecedented level of accuracy and speed that has the potential to redefine patient care.”

The Novel AI-Enhanced qMIDS Test stands as a testament to the relentless pursuit of innovation in healthcare. By combining the expertise of multiple leading institutions, this research initiative underscores the commitment of all parties involved to transform the landscape of oral cancer detection and management.

As the research continues to progress, the collaborative efforts of Curenetics, Queen Mary University London, Oracle Cancer Trust, SEHTA and NIHR stand poised to redefine the future of oral cancer diagnostics, exemplifying the profound impact that can be achieved through the integration of AI and cancer medicine.